Poster Authors:

Delia Brustur¹ , Jennifer Borthwick¹, Peng Chen², Carina Davies¹, Ping Huang³, Jeff Kennedy¹, Christian Kuper¹, John Maclean¹, Daniel Moseley¹, Benjamin Rahemtulla¹, Fran?ois Saint-Dizier¹, Owen Smith¹, Zixuan Tong¹, Marta Westwood¹, Han Zang², Qionglin Zhang³, Pengfei Zhang³

¹Pharmaron UK Ltd, West Hill Innovation Park, Hoddesdon, EN11 9FH

²Pharmaron, 1980 Guangde Road, Airport New City, Xixian New Area, China

³Pharmaron, 6 Taihe Road, BDA, Beijing, 100176, China

Fragment library expansion for enhanced chemical diversity

This poster was presented at the ELRIG Drug Discovery 2025.

The chemical landscape of clinical candidates and approved drugs is continually evolving. Pharmaron’s fragment library has been updated to represent these trends and to provide better starting points for medicinal chemistry campaigns. Our novel fragments are designed to increase chemical space coverage while ensuring attractive properties and high solubility. These improvements make the library ideally suited for SPR as a primary screening method, followed by orthogonal assays and structure-based development of potential hits – enabling more effective fragment-based drug discovery projects.

Key Insights of the Poster

• 25% library expansion with 550 carefully selected new fragments targeting underrepresented chemical space, enhancing the power of fragment library screening in your projects.
• Strategic chemical space coverage prioritizing optimum physical-chemical space  for high solubility and chemical tractability.
• Improved hit quality from our fragment screening services demonstrated a case study with the epigenetic reader BRD4.
• Rigorous quality control ensuring fragment solubility and stability through comprehensive QC workflow.